Xiaoke Liu

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Jacqulyne Robichaux, Xiuning Le, R. S. K. Vijayan et al. · Nature · 2021 · 452 citations · Full text

Medicine, Molecular Genetics, Oncology +14

Comprehensive T cell repertoire characterization of non-small cell lung cancer

Alexandre Reuben, Jiexin Zhang, Shin‐Heng Chiou et al. · Nature Communications · 2020 · 229 citations · Full text

Life Sciences, Immunology, Oncology +17

Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

Lingzhi Hong, Marcelo V. Negrão, Seyedeh Dibaj et al. · Journal of Thoracic Oncology · 2020 · 192 citations · Full text

Medicine, Immunology, Oncology +17

Knockdown of SUMO-activating enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances chemotherapy sensitivity in small cell lung cancer

Xiaoke Liu, Yong Xu, Zongguo Pang et al. · Journal of Hematology & Oncology · 2015 · 56 citations · Full text

Medicine, Cell Biology, Oncology +14

Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma?

Yan Zhang, Xiaoyu Li, Yuan Tang et al. · Lung Cancer · 2013 · 54 citations

Medicine, Cancer Biology, Oncology +16